The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer

Aim: We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. Materials & methods: We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients). Results: THOR was significan...

ver descrição completa

Detalhes bibliográficos
Autor principal: Faleiro, Inês (author)
Outros Autores: Apolónio, Joana (author), Price, Aryeh J. (author), De Mello, Ramon Andrade (author), Roberto, Vânia (author), Tabori, Uri (author), Castelo-Branco, Pedro (author)
Formato: article
Idioma:eng
Publicado em: 2019
Assuntos:
Telomerase
Expression
Carcinoma
Texto completo:http://hdl.handle.net/10400.1/12962
País:Portugal
Oai:oai:sapientia.ualg.pt:10400.1/12962
Descrição
Resumo:Aim: We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. Materials & methods: We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients). Results: THOR was significantly hypermethylated in pancreatic tumor tissue when compared with the normal tissue used as control (p < 0.0001). Also, THOR hypermethylation could distinguish early stage I disease from normal tissue and was associated with worse prognosis. Discussion: We found that THOR is hypermethylated in pancreatic tumor tissue when compared with normal tissue and that THOR methylation correlates with TERT expression in tumor samples. Conclusion: Our preliminary findings support the diagnostic and prognostic values of THOR in pancreatic cancer.

Registros relacionados